Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

被引：0
|
作者：
Zoltán Vokó
László Nagyjánosi
Zoltán Kaló
机构：
[1] Eötvös Loránd University,Department of Health Policy & Health Economics, Institute of Economics, Faculty of Social Sciences
[2] Syreon Research Institute,undefined
[3] National Institute for Health Development,undefined
来源：
BMC Public Health | / 12卷
关键词：
Cervical cancer; Human papillomavirus; Vaccine; Cervarix; Hungary; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10-18 Years
    Petaja, Tiina
    Keranen, Heli
    Karppa, Tiina
    Kawa, Anna
    Lantela, Sirkku
    Siitari-Mattila, Mari
    Levanen, Helena
    Tocklin, Tuomas
    Godeaux, Olivier
    Lehtinen, Matti
    Dubin, Gary
    JOURNAL OF ADOLESCENT HEALTH, 2009, 44 (01) : 33 - 40
  • [32] Re: Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination
    Giorgi Rossi, Paolo
    Zappa, Marco
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (22): : 1654 - 1654
  • [33] Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening
    Thiry, Nancy
    De Laet, Chris
    Hulstaert, Frank
    Neyt, Mattias
    Huybrechts, Michel
    Cleemput, Irina
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (02) : 161 - 170
  • [34] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    Donna Lawrence
    Jennifer Haig
    Andrea Anonychuk
    Nadia Demarteau
    BMC Public Health, 12
  • [35] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Kohli, Michele
    Lawrence, Donna
    Haig, Jennifer
    Anonychuk, Andrea
    Demarteau, Nadia
    BMC PUBLIC HEALTH, 2012, 12
  • [36] Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan
    Liu, Pang-Hsiang
    Hu, Fu-Chang
    Lee, Ping-Ing
    Chow, Song-Nan
    Huang, Chao-Wan
    Wang, Jung-Der
    BMC HEALTH SERVICES RESEARCH, 2010, 10
  • [37] Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan
    Pang-Hsiang Liu
    Fu-Chang Hu
    Ping-Ing Lee
    Song-Nan Chow
    Chao-Wan Huang
    Jung-Der Wang
    BMC Health Services Research, 10
  • [38] Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls
    Schmeink, Channa E.
    Bekkers, Ruud L. M.
    Josefsson, Ann
    Richardus, Jan H.
    Blom, Katarina Berndtsson
    David, Marie-Pierre
    Dobbelaere, Kurt
    Descamps, Dominique
    VACCINE, 2011, 29 (49) : 9276 - 9283
  • [39] Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls
    Pedersen, Court
    Breindahl, Morten
    Aggarwal, Naresh
    Berglund, Johan
    Oroszlan, Gyoergy
    Silfverdal, Sven Arne
    Szuts, Peter
    O'Mahony, Michael
    David, Marie-Pierre
    Dobbelaere, Kurt
    Dubin, Gary
    Descamps, Dominique
    JOURNAL OF ADOLESCENT HEALTH, 2012, 50 (01) : 38 - 46
  • [40] Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine reply
    Lehtinen, Matti
    LANCET ONCOLOGY, 2012, 13 (02): : E50 - E50
12345